AbCellera Biologics Inc.

NASDAQ: ABCL · Real-Time Price · USD
4.58
0.08 (1.78%)
At close: Aug 15, 2025, 3:59 PM
4.61
0.66%
After-hours: Aug 15, 2025, 07:54 PM EDT

AbCellera Biologics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
4.24M 5.05M 6.51M 7.32M 9.95M 9.18M 6.6M 10.06M 12.19M 21.55M 101.38M 45.92M 316.58M 139.33M 5.51M 27.64M 202.74M
Cost of Revenue
42.5M 13.9M 38.3M 38.04M 6.77M 9.11M 7.41M 7.26M 52.65M 1.55M 15.04M 5.21M 44.64M 21.89M 17.45M 3.61M 20.01M
Gross Profit
-38.26M -8.85M -31.79M -30.71M 3.19M 70K -810K 2.8M -40.45M 19.99M 86.35M 40.71M 271.94M 117.44M -11.94M 24.03M 182.73M
Operating Income
-105.16M -72.75M -93.66M -93.45M -54.89M -66.05M -54.89M -51.39M -61.5M -37.78M 37.73M -6.86M 224.95M 81.55M -28.1M -7.03M 158.07M
Interest Income
n/a 8.67M 9.6M 9.8M 10.4M 10.97M 10.74M 10.78M 9.76M n/a 5.56M 1.41M 665K n/a n/a n/a n/a
Pretax Income
-52.98M -46.83M -62.63M -48.19M -42.75M -48.6M -39.28M -38M -48.15M -31.41M 46.59M -6.89M 230.81M 84.71M -24.97M -2.07M 161.49M
Net Income
-45.62M -34.21M -51.11M -36.93M -40.61M -47.15M -28.61M -30.53M -40.11M -29.89M 26.62M -6.79M 168.57M 59.95M -21.38M -2.32M 117.22M
Selling & General & Admin
19.07M 19.16M 22.28M 23.33M 20.72M 19.07M 17.84M 19.36M 18.91M 15.71M 16.88M 17.53M 16.64M 14.72M 12.49M 12.5M 9M
Research & Development
42.5M 46.08M 40.97M 40.93M 39.29M 48.62M 37.92M 36.47M 52.65M 28.25M 26.58M 26.68M 26.37M 17.21M 17.45M 15.05M 12.35M
Other Expenses
5.33M 12.56M 36.92M 32.16M -1.53M 3.11M 2.05M -1.97M 2.14M 13.82M 3M 3.35M -1.2M -1.35M -1.26M 314K 265K
Operating Expenses
66.89M 77.81M 100.17M 62.74M 58.08M 71.86M 58.66M 56.87M 73.69M 57.77M 46.46M 47.57M 41.8M 30.57M 29.22M 26.42M 21.51M
Interest Expense
8.05M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
2.84M 3.14M 3.13M 3.14M 3.37M 3.1M 3.47M 3.84M 3.77M 2.69M 3.09M 3.12M 2.37M 1.83M 1.22M 1.29M 2.58M
Cost & Expenses
109.39M 77.81M 100.17M 100.78M 64.85M 71.86M 58.66M 56.87M 73.69M 59.32M 61.5M 52.78M 86.44M 52.47M 29.22M 30.03M 41.52M
Income Tax Expense
-7.36M -12.62M -11.53M -11.26M -2.14M -1.45M -10.67M -7.48M -8.04M -1.52M 19.96M -101K 62.24M 24.76M -3.59M 250K 44.27M
Shares Outstanding (Basic)
297.69M 295.76M 294.85M 294.22M 292.72M 290.05M 289.5M 288.91M 287.77M 286.41M 315.82M 284.69M 311.48M 278.93M 267.25M 272.2M 269.7M
Shares Outstanding (Diluted)
297.69M 295.76M 294.85M 294.22M 292.72M 290.05M 289.5M 288.91M 287.77M 301.3M 315.82M 284.69M 311.48M 278.93M 278.93M 272.2M 320.28M
EPS (Basic)
-0.15 -0.12 -0.17 -0.13 -0.14 -0.16 -0.1 -0.11 -0.14 -0.1 0.08 -0.02 0.54 0.21 -0.08 -0.01 0.43
EPS (Diluted)
-0.15 -0.12 -0.17 -0.13 -0.14 -0.16 -0.1 -0.11 -0.14 -0.1 0.08 -0.02 0.54 0.21 -0.08 -0.01 0.37
EBITDA
-39.6M -55.31M -51.88M -56.93M -48.13M -58.52M -44.65M -39.56M -59.36M -4.66M 53.31M -845K 235.78M 94.8M -20.77M 2.14M 165.45M
EBIT
-44.93M -47.63M -90.17M -90.14M -51.62M -62.68M -52.06M -46.81M -61.5M -20.02M 37.73M -6.86M 224.95M 81.55M -24.97M -2.39M 158.07M
Depreciation & Amortization
5.33M 13.9M 38.3M 38.04M 6.77M 9.11M 7.41M 7.26M 7.12M 15.36M 6.73M 6.04M 4.97M 4.86M 4.21M 4.21M 3.97M